Catheter-Based Therapies for Patients With Medication-Refractory Pulmonary Arterial Hypertension

Leopold, Jane A.

doi:10.1161/circinterventions.115.003332

Cited by 13 publications

(5 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Similar results were reported at the 1-year follow-up for 66 patients with PH of varied etiology in the Phase-II PADN-1 study 4 . Even though these results were promising, they were taken with caution by the PH community given the limitations of the study design (reduced number of patients, lack of randomization, absence of control group, withdrawal of targeted therapies in PADN patients, unusual baseline characteristics of the patient population not matching most idiopathic PH series and short-term follow-up) 8,17 and the need for a controlled trial was internationally recognized 13 . Finally, in the very recent study by Zhang et al 12 , a series of 10 cases with PH secondary to HF treated with percutaneous PADN was reported.…”

Section: Discussionmentioning

confidence: 99%

Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study

et al. 2019

View full text Add to dashboard Cite

The authors thank Gonzalo J. López for the high-quality cardiac magnetic resonance examinations. Tamara Córdoba, Oscar Sanz, Nuria Valladares, Eugenio Fernández and the rest of the staff working in the animal facilities and CNIC ś farm were outstanding in animal care and unconditional collaboration. Laura García, Alberto Barroso and Xavier Navarro provided us with the ablation clamps and catheters and assisted us during the denervation procedures. Paula Garcia-Lunar provided valuable support with tissue sampling when it was most needed. SOURCES OF FUNDING:This work has been partially funded by the grant "Translational research project from the Sociedad Española de Cardiología" (to Dr. García-Álvarez) and by an unrestricted grant from Medtronic. The CNIC is supported by the Ministerio de Ciencia, Innovación y Universidades and the Pro CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505).IDIBAPS belongs to the CERCA Programme and receives partial funding from the Generalitat de Catalunya.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Эти факты, а также развитие в последнее время ренальной денервации в лечении резистентной ЛГ стали ключевыми для начала исследований легочной денервации у пациентов с ЛАГ [9].…”

Section: экспериментальные исследованияunclassified

Pulmonary artery denervation in patients with pulmonary hypertension: present state and clinical experience

et al. 2019

View full text Add to dashboard Cite

Despite treatment advances, the prognosis of patients with both primary and secondary pulmonary hypertension (PH) remains unfavorable. The increased activity of the sympathetic nervous system is one of the universal mechanisms involved in the PH pathogenesis. Pulmonary artery denervation is a novel minimally invasive pathogenetic method of PH treatment. The denervation procedure is mainly implemented by using radiofrequency ablation of the pulmonary trunk, where most sympathetic nerve fibers are located. In this article we present an overview and analysis of the present state, results of various experimental and clinical studies, as well as clinical experience. The results of studies demonstrated the safety of endovascular surgery and its beneficial effect on both hemodynamic and clinical parameters.

show abstract

“…Pulmonary arterial hypertension (PAH), characterized by mean pulmonary artery pressure (mPAP) ≥ 25 mmHg at rest, pulmonary artery wedge pressure (PAWP) ≤ 15 mmHg and pulmonary vascular resistance (PVR) > 3 Wood units [ 1 ], is a disease induced by a wide range of causes, which makes it difficult to formulate an appropriate therapeutic plan and receive great responses for PAH patients [ 2 ]. Up till the present, most patients can only rely on combined targeted medicine, however, not all patients can be relieved [ 2 , 3 ]. Besides, the 1-year, 3-year and 5-year survival rate of medium to high-risk patients treated by target therapy are 90%, 61%, 43% [ 4 ], and side effects of targeted medicine are not tolerable in a considerable number of patients.…”

Section: Introductionmentioning

confidence: 99%

The progress of pulmonary artery denervation

et al. 2022

View full text Add to dashboard Cite

show abstract

Catheter-Based Therapies for Patients With Medication-Refractory Pulmonary Arterial Hypertension

Cited by 13 publications

References 21 publications

Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study

Effect of pulmonary artery denervation in postcapillary pulmonary hypertension: results of a randomized controlled translational study

Pulmonary artery denervation in patients with pulmonary hypertension: present state and clinical experience

The progress of pulmonary artery denervation

Contact Info

Product

Resources

About